Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
 

Life Sciences

full industries list
Life Sciences Image
News
Events
Litigation Blog
Hatch-Waxman

Fish  attorneys have served as leading advisors to pioneers in the pharmaceutical, biotechnology, and life sciences fields for more than a century. For three consecutive years, we have been named the top US law firm for life sciences and biotechnology IP work by Managing Intellectual Property magazine. Clients choose Fish because of the technical and scientific expertise of our internationally recognized attorneys.

Large and small companies, along with academic and research institutions, turn to Fish’s team to protect their most valuable innovations. We offer biotechnology and pharmaceutical clients services that include:

  • Patent portfolio planning, strategic advice, opinions, and prosecution
  • Post-grant proceedings at the USPTO
  • Litigation services, including representation in Hatch-Waxman cases
  • FDA expertise
  • Counsel on licensing and other transactions

We have a rapidly expanding practice representing branded pharmaceutical companies in Hatch-Waxman litigation. Biotechnology and pharmaceutical companies trust Fish’s litigation team to handle these complicated, high-stakes cases because we are the world’s most experienced patent litigators.

Examples of our biotechnology and pharmaceutical work include:

  • Representing dozens of biotechnology and pharmaceutical clients in patent infringement litigation
  • Successfully litigating ANDA cases on behalf of branded pharmaceuticals
  • Obtaining patents for therapeutic agents and methods currently in clinical trials, including tumor-specific agents such as oncolytics viruses and humanized antibodies and methods for treating strokes
  • Patenting groundbreaking tissue engineering patents on breakthroughs that show promise in treating spinal cord injuries
  • Obtaining the first patent on a genetically engineered animal
  • Gaining FDA approvals for small molecule drugs and biologics, including gene and cell therapies, antibiotics, immunologics, and anti-anxiety medications
  • Conducting intellectual property due diligence on thousands of licensing agreements for the merger of two large pharmaceuticals companies in just a few months’ time

Notable Wins

Fish Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead

Fish won a unanimous Federal Circuit opinion today that affirmed its June 2016 post-trial wipe-out of a $200 million jury verdict against client Gilead Sciences, Inc. after proving Merck had forfeited its right to assert its hepatitis C drug patents against Gilead because of litigation and business misconduct constituting “unclean hands.”

Read more about this precedential opinion here and here.

Fish Wipes Out $2.5B Patent Verdict Against Gilead Sciences

Fish & Richardson won a motion for Judgment as a Matter of Law (JMOL) that reversed a $2.5 billion jury verdict against its client Gilead Sciences Inc. in federal court in Delaware.

Read about this historic win here and here.

 General Patent Litigation Firm of the Year: Fish & RichardsonPatent Impact Case of the Year: Fish & Richardson

Intellectual Property (IP) Firm of the YearIntellectual Property (IP) Practice Group of the Year

Search Fish Team

Search by Letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
No matches
Life Sciences

Life Sciences Team

What's Trending in Life Sciences

Filter by
Event
十一月 16th, 2020 | 3:00 上午 EST
Bio Integrates 2020
Speaking Engagement
Conference/Convention
Event
十二月 2nd, 2020 | 1:30 下午 EST
Webinar | How To Prevent a Terrible, Horrible, No Good, Very Bad Day for Your Life Sciences Start-up: Lessons Learned From Company Formation, Drug Development, Partnering, and Due Diligence Nightmares
Webinar
Event
十月 21st, 2020 | 2:00 下午 EST
NJIPLA - 34th Annual Pharmaceutical/Chemical Patent Practice Update Webinar Series
Speaking Engagement
Webinar
Event
八月 13th, 2020 | 1:30 下午 EST
Webinar | The Impact of Patent Term Extension on Litigation Under the Hatch-Waxman Act: A Look at the Federal Circuit’s Recent Decision in Biogen v. Banner Life Scis.
Webinar
Event
七月 13th, 2020 | 12:00 上午 GMT
One Nucleus: ON Helix Conference - Transforming New Medicine Discovery
Speaking Engagement
Event
七月 30th, 2020 | 1:30 下午 EST
Webinar | Structuring Biotech & Pharma Startup Portfolios for Global Impact, Value, and Partnering
Webinar
Event
七月 23rd, 2020 | 1:30 下午 EST
Webinar | Biosimilars: A 2020 Mid-Year Review
Webinar
Event
七月 21st, 2020 | 1:30 下午 EST
Webinar | Navigating to the Safe Harbor: What to Know in Advance
Webinar
Event
六月 25th, 2020 | 1:00 下午 PST
Xconomy: The AI, Big Data, and R&D Boom
Speaking Engagement
Sponsorship
Event
七月 7th, 2020 | 1:30 下午 EST
Webinar | Antitrust Implications of Biologic Patent Settlements
Webinar
Event
六月 23rd, 2020 | 1:30 下午 EST
Webinar | Special Topics Related to Obviousness in the Context of Drug Development
Webinar
Event
六月 16th, 2020 | 1:30 下午 EST
Webinar | Hatch-Waxman: Positioning Your Company For Success Against Generic Challenges
Webinar
load more topics